Serum Institute to resume India trial of AstraZeneca's COVID-19 vaccine -report
- Country:
- India
India's drugs regulator has given approval to Serum Institute of India to resume local clinical trials of the potential COVID-19 vaccine developed by AstraZeneca and Oxford University, the Times of India reported on Wednesday, citing the Press Trust of India.
Serum did not immediately respond to Reuters requests for comment. The Drugs Controller General of India did not return an email seeking comment.
ALSO READ
-
Japanese Lawmakers Visit India to See Worker Protection and Skills Projects in Action
-
Indian Unions Push for Fair Recruitment and Rights for Care Workers in Germany
-
African Venture Capital Gets a Boost as Oxford Programme Builds Investor Connections
-
Cleaner Kitchens, Polluted Skies: Hidden Health Cost of India’s Electricity Boom
-
Japan-Backed ILO Projects Help 23,000 Workers Gain Rights and Fight Child Labour
Google News